Canaccord Genuity Starts Akari Therapeutics (AKTX) at Buy
Tweet
Share
E-mailGet Alerts AKTX Hot Sheet
Price: $1.19 --0%
Rating Summary:
5 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Rating Summary:
5 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
Canaccord Genuity initiated coverage on Akari Therapeutics (NASDAQ: AKTX) with a Buy rating and a price target of $33.00.
For an analyst ratings summary and ratings history on Akari Therapeutics click here. For more ratings news on Akari Therapeutics click here.
Shares of Akari Therapeutics closed at $16.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Singular Research Starts Citizens Inc. (CIA) at Buy-Long Term, 'Proven Distribution Growth'
- Wells Fargo Starts Americold Realty Trust (COLD) at Equal Weight
- Spotify (SPOT) PT Raised to $330 at Canaccord Genuity
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
